Insilico Medicine uses generative artificial intelligence for drug discovery and development, focusing on significantly reducing the time and cost to bring medications to patients.

Insilico Medicine

Amazon

DMARC

Google Apps for Business

Microsoft Azure DNS

GoDaddy DNS

AWS Global Accelerator

Apple iCloud Mail

Atlassian Cloud

Zoom

Engineering

Aggie Hsin-I Chen

Director, Nonclinical Development and Safety

Collin Bantle

IT Director

Daniil Polykovskiy

Business Management

Luoheng Qin

Associate Director Business Development

Sean Cullen

Associate Director of Bioinformatics

Shan Chen

Associate Director, Technology Partnership

Ying-Ja Chen

Head of PR | Strategy | PR | Media Relations | Communications

Brita Belli

Information Technology

Evgeniia Ondar

Regulatory Affairs Manager

Hehaoyu Zou

Kristen Fortney

Min Fang

Nisa Leung

Garri Zmudze

Alex Zhavoronkov

Founder & Chief Executive Officer

Qingsong Zhu

Michael Bayewitch

Vice President of Business Development and Strategy

Michelle Chen

Chief Business Officer

Robert Spiegel

Chief Medical Officer

Alex Aliper

President of EMEA

Vladimir Naumov

bioinformatics data scientist

Nirav Jhaveri

Chief Financial Officer

Private Equity Funded Companies (Top 10K)

Asia Companies (Top 10K)

Health Care Companies With Less Than $500M in Revenue (Top 10K)

Companies With Less Than $500M in Revenue (Top 10K)

Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases. It pioneered the applications of the generative adversarial networks (GANs), reinforcement learning, transfer learning, and meta-learning for the generation of novel molecular structures for the diseases with known and unknown targets, and, unlike the other companies in the field, is developing the end-to-end pipeline covering every step of drug discovery, clinical trials analysis, and digital medicine. Insilico Medicine is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with Life Extension, the company launched a range of nutraceutical products, which were compounded using advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

Prosperity7 Ventures

Series D - Insilico Medicine

Fosun Pharma

Corporate Round - Insilico Medicine

Warburg Pincus

Series C - Insilico Medicine

Qiming Venture Partners

Series B - Insilico Medicine

WuXi AppTec

Series A - Insilico Medicine

Deep Knowledge Group

Convertible Note - Insilico Medicine

Seed Round - Insilico Medicine

Computer and Software Products and Electrical and Scientific Products

Hong Kong

Hong Kong Island

Asia

Insilico announces positive topline results for IPF treatment

Artificial Intelligence in Drug Discovery Market to Hit USD 6.89 Billion by 2029 with 29.9% CAGR | MarketsandMarkets™

Insilico Medicine Announces Positive Topline Results of ISM001-055 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) Developed Using Generative AI

Insilico Medicine divulges novel HPK1 inhibitor with robust antitumor activity

Insilico Medicine discovers CDK8/19 dual inhibitors

Insilico Medicine divulges new Mpro inhibitors for SARS-CoV-2

Insilico Medicine partners with Inimmune to advance immunotherapeutic discovery

Insilico Medicine discloses new PTPN2 inhibitors

Insilico Medicine launches AI assistant for drafting medical research papers

AI for Good: Insilico Medicine Hosts IMGAIA Product Launch Event

An AI-driven drug discovery platform that accelerates disease target identification, novel molecule generation, and clinical trial outcome prediction.

A platform for comprehensive pathway analysis and target hypothesis generation using a combination of text and omics data.

A generative chemistry platform for designing novel small molecules with specific properties and annotations.

A platform for data-driven multimodal forecasting of clinical trial success probabilities, optimizing trial design, and de-risking pharmaceutical portfolios.

A scalable platform for biologics discovery and development, operating across distributed computing environments.

A small-molecule drug designed to treat fibrosis-related indications, including idiopathic pulmonary fibrosis, and the first generative AI-designed drug for an AI-discovered target to reach Phase II trials.

United States

North America

Switzerland

Europe

Germany

India

Nigeria

Africa

HTML5

Google Tag Manager

Google Drive

F5 NGINX

Vimeo

jQuery

Google Analytics

Google Fonts

GoDaddy Premium DNS

Google Maps API

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 1, 2024 7:24 PM	6d4bb10e
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 1, 2024 7:24 PM	a277c241
crunchbase trigger	general	Nov 22, 2024 7:44 AM	1cecdc7b
crunchbase profile	general	Nov 22, 2024 10:24 AM	30f62b5e
li profile	general
translate crunchbase fundingrounds	general	Nov 22, 2024 2:21 PM	2e959b85
peers	general	Oct 1, 2024 7:24 PM	ea57021e
news basic	general	Oct 1, 2024 7:24 PM	e56e42c5
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:INSILICO

Insilico Medicine